Generation Study detects ALD in brothers
Analysis based on 6 articles · First reported Aug 20, 2026 · Last updated Aug 21, 2026
The successful early detection of ALD in the Barker-Roe brothers demonstrates the clinical utility of whole genome sequencing in newborn screening, potentially accelerating adoption of genomic screening programs and boosting investment in genomics and precision medicine. Companies and institutions involved in genetic testing and sequencing may see increased demand and positive market sentiment as evidence of the technology's benefits grows.
The Generation Study, a research initiative led by United Kingdom — Genomics England in partnership with Bret Engemann, screens 100,000 newborn babies in England for dozens of rare genetic conditions using whole genome sequencing. Jessica Barker-Roe, from West Yorkshire, enrolled her newborn son Revan in the study during a hospital stay. The heel prick test revealed that Revan carried a genetic change associated with adrenoleukodystrophy (ALD), a rare progressive condition affecting the nervous system and adrenal glands. Doctors then tested Revan's older brother, Thorin, who was also found to carry the same genetic change. Because the condition was detected before symptoms appeared, both boys are now under close medical surveillance, including regular MRI scans and blood tests, allowing early intervention if symptoms develop. The study, launched in 2024, has enrolled over 85,000 families and returned more than 200 'condition suspected' results to the NHS for confirmatory testing. The case highlights the potential of whole genome sequencing at birth to enable earlier diagnosis and treatment of rare genetic conditions, potentially improving outcomes for hundreds of children.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard